- Home
- ABSI vs CRVS Comparison
ABSI vs CRVS Comparison
Compare ABSI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- CRVS
- Stock Information
- Founded
- ABSI 2011
- CRVS 2014
- Country
- ABSI United States
- CRVS United States
- Employees
- ABSI N/A
- CRVS N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- CRVS Health Care
- Exchange
- ABSI Nasdaq
- CRVS Nasdaq
- Market Cap
- ABSI 505.4M
- CRVS 459.0M
- IPO Year
- ABSI 2021
- CRVS 2016
- Fundamental
- Price
- ABSI $3.79
- CRVS $7.01
- Analyst Decision
- ABSI Strong Buy
- CRVS Strong Buy
- Analyst Count
- ABSI 6
- CRVS 3
- Target Price
- ABSI $7.98
- CRVS $13.00
- AVG Volume (30 Days)
- ABSI 5.8M
- CRVS 772.5K
- Earning Date
- ABSI 11-11-2025
- CRVS 11-11-2025
- Dividend Yield
- ABSI N/A
- CRVS N/A
- EPS Growth
- ABSI N/A
- CRVS N/A
- EPS
- ABSI N/A
- CRVS N/A
- Revenue
- ABSI $4,138,000.00
- CRVS N/A
- Revenue This Year
- ABSI $41.73
- CRVS N/A
- Revenue Next Year
- ABSI $384.22
- CRVS N/A
- P/E Ratio
- ABSI N/A
- CRVS N/A
- Revenue Growth
- ABSI 27.32
- CRVS N/A
- 52 Week Low
- ABSI $2.01
- CRVS $2.54
- 52 Week High
- ABSI $6.33
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- ABSI 73.13
- CRVS 62.35
- Support Level
- ABSI $2.48
- CRVS $6.76
- Resistance Level
- ABSI $3.70
- CRVS $7.39
- Average True Range (ATR)
- ABSI 0.24
- CRVS 0.42
- MACD
- ABSI 0.13
- CRVS 0.03
- Stochastic Oscillator
- ABSI 95.81
- CRVS 67.38
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).